^
Association details:
| Biomarker: | ER Y537S |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) + gedatolisib (PF-05212384) (mTOR inhibitor, PI3K inhibitor, mTORC1 inhibitor, mTORC2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Biomarker analysis from a phase I study using gedatolisib+palbociclib+hormone therapy in ER+/HER2- metastatic breast cancer (mBC).
Published date:
05/13/2020
Excerpt:
Of the 6 pts with an ESR1 mutation, 1 pt with an ESR1 Y537S mutation exhibited a partial response (PR) to G+P+L. Longitudinal plasma ctDNA analysis (73-gene panel) revealed that decreases in PIK3CA and PTEN were most associated with clinical response....The addition of G to SOC endocrine + CDKi therapy may help overcome resistance due to activation of FGFR or EGFR signaling pathways and the ESR1 Y537S mutation.
Secondary therapy:
letrozole
DOI:
10.1200/JCO.2020.38.15_suppl.1052
Trial ID:
